Market Overview

Dr. Wellington Sun Joins Moderna as Head, Vaccine Strategy and Regulatory Affairs

Share:

Moderna, Inc., a clinical stage biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines to create a new
generation of transformative medicines for patients, today announced
that Dr. Wellington Sun will join the company as its Head, Vaccine
Strategy and Regulatory Affairs, starting later this month. Dr. Sun
comes to Moderna from the U.S. Food and Drug Administration (FDA), where
he was Director of the Division of Vaccines and Related Product
Applications at the Center for Biologics Evaluation and Research (CBER).
Dr. Sun will report to Dr. Tal Zaks, M.D., Chief Medical Officer of
Moderna.

"We are delighted to welcome Wellington to Moderna. As an infectious
disease specialist and with extensive experience in vaccine research,
regulatory affairs and clinical trial design, he is uniquely qualified
to shape our development strategy as we work to advance our broad
portfolio of mRNA-based development candidates," said Dr. Zaks.

Moderna has 21 mRNA development candidates in its pipeline with 10 in
clinical development. This includes nine infectious disease vaccine
programs, with seven currently in Phase 1 trials.

"I look forward to bringing my clinical, scientific and regulatory
experience to help realize the potential of mRNA technology in
preventing intractable infectious diseases through the development of
safe and effective vaccines," said Dr. Sun. "I am excited to work with
the team here to identify new development candidates while progressing
the portfolio of existing clinical programs."

During his decade-long tenure at the FDA, Dr. Sun oversaw approvals of
28 original infectious disease vaccine applications and more than 100
supplement applications for new indications. While there, he worked
closely with partners including the Centers for Disease Control and
Prevention (CDC), the National Institutes of Health and the Biomedical
Advanced Research and Development Authority, on infectious disease
vaccine issues and policies. He also worked with the World Health
Organization and global regulatory agencies to address clinical trial
and regulatory issues related to emerging infectious diseases such as
the H1N1 pandemic and Ebola and Zika epidemics.

Dr. Sun joined the FDA from the CDC, where he led field and laboratory
research on Dengue fever and West Nile virus, and was principal
investigator of the first-ever controlled human infection trial in
subjects previously vaccinated with tetravalent dengue vaccines. Prior
to the CDC, he served for 27 years in the U.S. Army Medical Corps,
working as both a clinician and then as a vaccine researcher at the
Walter Reed Army Institute of Research. While there he led the
Department of Defense respiratory adenovirus and flavivirus basic and
clinical research programs.

Dr. Sun holds an M.D. from Uniformed Services University of the Health
Sciences and a B.A. from Harvard University. He is board certified in
both Internal Medicine and Infectious Disease.

About Moderna, Inc.

Moderna pioneers the discovery and development of messenger RNA (mRNA)
therapeutics and vaccines, an entirely new class of medicines that
directs the body's cells to produce intracellular or secreted proteins
that can have a therapeutic or preventive benefit for both patients and
healthy individuals. With its breakthrough platform, Moderna is creating
mRNA medicines for a wide range of diseases and conditions, in many
cases by addressing currently undruggable targets or underserved areas
of medical need. Moderna is developing its innovative mRNA medicines for
infectious diseases, immuno-oncology, rare diseases, and cardiovascular
diseases, through solely controlled programs and collaborations with
strategic partners.

Headquartered in Cambridge, Mass., privately held Moderna currently has
strategic relationships with AstraZeneca, Plc. (AZ), Merck, Inc. (MRK)
and Vertex Pharmaceuticals (VRTX), as well as the Defense Advanced
Research Projects Agency (DARPA), an agency of the U.S. Department of
Defense; the Biomedical Advanced Research and Development Authority
(BARDA), a division of the Office of the Assistant Secretary for
Preparedness and Response (ASPR) within the U.S. Department of Health
and Human Services (HHS); and the Bill & Melinda Gates Foundation. In
2017, Moderna was ranked a top biopharma industry employer by Science and
a Top Place to Work by the Boston
Globe
. To learn more, visit www.modernatx.com.

View Comments and Join the Discussion!